Authors: Prof Rhonda R Voskuhl, MD
, HeJing Wang, MD
, T C Jackson Wu, MD
, Nancy L Sicotte, MD
, Kunio Nakamura, PhD
, Florian Kurth, PhD
, Noriko Itoh, MS
, Jenny Bardens, RN
, Jacqueline T Bernard, MD
, Prof John R Corboy, MD
, Prof Anne H Cross, MD
, Prof Suhayl Dhib-Jalbut, MD
, Prof Corey C Ford, MD
, Prof Elliot M Frohman, MD
, Prof Barbara Giesser, MD
, Dina Jacobs, MD
, Prof Lloyd H Kasper, MD
, Prof Sharon Lynch, MD
, Prof Gareth Parry, MD
, Prof Michael K Racke, MD
, Prof Anthony T Reder, MD
, Prof John Rose, MD
, Prof Dean M Wingerchuk, MD
, Allan J MacKenzie-Graham, PhD
, Prof Douglas L Arnold, MD
, Chi Hong Tseng, PhD
, Prof Robert Elashoff, PhD
Summary:
Relapses of multiple sclerosis decrease during pregnancy, when the hormone estriol is increased. Estriol treatment is anti-inflammatory and neuroprotective in preclinical studies. In a small single-arm study of people with multiple sclerosis estriol reduced gadolinium-enhancing lesions and was favourably immunomodulatory. We assessed whether estriol treatment reduces multiple sclerosis relapses in women.
Source:
The Lancet Neurology; Vol. 15, No. 1, 35-46 (01/2016)